Shukla Sath's Form 4 filing
Spero Therapeutics, Inc. (SPRO) · filed Feb 5, 2025
- Accession no.
- 0000950170-25-014850
- Filed
- Feb 5, 2025
- Trade date
- Feb 3-5, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $121.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shukla SathCIK 0001782817 | Officer (CEO & President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 3, 2025 | Common Stock | AGrant or awardAcquired | +751,407 | $0.00 | $0 | 1,892,216 | Direct | |
| Feb 5, 2025 | Common Stock | SSaleDisposed | −6,139 | $0.78 | −$4,788.42 | 1,886,077 | Direct | |
| Feb 5, 2025 | Common Stock | SSaleDisposed | −42,786 | $0.78 | −$33,373.08 | 1,843,291 | Direct | |
| Feb 5, 2025 | Common Stock | SSaleDisposed | −106,408 | $0.78 | −$82,998.24 | 1,736,883 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.